Moderna stock pops after Oppenheimer says Covid shot maker could launch more products over next two years
[ad_1]
The upgrade follows a dismal 2023 for Moderna, whose only commercially available product is its Covid shot.
[ad_2]
Source link
[ad_1]
The upgrade follows a dismal 2023 for Moderna, whose only commercially available product is its Covid shot.
[ad_2]
Source link